Allergan plc, of Dublin, reported total net revenues of $3.7 billion for its second quarter 2016 financial, a 2 percent increase vs. the prior year quarter. The company said its results were impacted by the loss of exclusivity on Namenda IR, offset by strong performance in key brands such as Botox and Restasis and new product launches. GAAP operating loss from continuing operations in the second quarter 2016 was $488 million. Cash flow from operations was $1.4 billion. As of June 30, the company had cash and marketable securities of $507 million and outstanding indebtedness of $39.6 billion. Allergan announced it plans to begin a $5 billion share repurchase program over the remainder of the year.